Searched for
COVID PATIENT
These large-, mid- and small-cap stocks can give more than 25% return in 1 year, according to analystsAs the old saying goes: Nothing can be ruled out on the street. Which means that one should be prepared for anything. Now, what is the prob...- U. S government health CDC journal blocked COVID-19 vaccine study but paper has finally been published. What is in it? Details hereCovid-19 study approach, called "test-negative design", looks at people who were admitted to hospitals or visited emergency rooms with resp...
- L’Oréal adds Innovist to cart; HealthQuad's new fundHappy Friday! Personal care giant L’Oreal has acquired a majority stake in Innovist in India’s biggest D2C deal. This and more in today’s E...
- Death rate in ICE immigrant detention centers more than doubles under Trump, Reuters analysis findsFifty individuals have died in U.S. immigration detention since January 2025, a rate that has more than doubled since 2009. Concerns are ri...
- These large-caps have ‘strong buy’ & ‘buy’ recos and an upside potential of up to 27%As the market seems to be in comeback mode, it helps to be aware that the best (and probably biggest) wealth creator of the last couple of ...
- ETMarkets Smart Talk | Defence and electrification are multi-year structural themes for India: Prateek AgrawalGeopolitical shifts and the drive for self-reliance are creating long-term investment opportunities in India's defence and electrification ...
- No Covid, yet Rs 3.71 lakh hospital bill: Gujarat man's insurance paid only Rs 1.78 lakh, deducting Rs 1.64 lakh; Then court delivered justiceA Gujarat consumer commission ordered a hospital and doctor to refund Rs 1.64 lakh to a patient. The patient was wrongly billed under a Cov...
- These large- and mid-cap stocks can give more than 25% return in 1 year, according to analystsThere are market phases when one risk dominates. Then there are phases like this, when risks arrive from every direction and refuse to stan...
- Over 1,500 bat species carry thousands of deadly viruses but rarely get sick, and scientists are only just beginning to understand whyBats possess a unique, preactivated innate immune defense that stops viruses from fully replicating, even after cell entry. This remarkable...
- India's healthcare transformed in 12 years under PM Modi: ReportIndia's healthcare sector has seen a major transformation over the last 12 years. Health insurance coverage has expanded significantly. Mat...
- ET Alpha Wealth Summit: Rajeev Thakkar of PPFAS MF explains when to hold, when to exit, and why most investors get it wrongPPFAS CIO Rajiv Thakkar said successful investing depends more on patience than frequent trading. He advised avoiding unnecessary selling, ...
- Avammune’s big bet: Why the future of cancer treatment may come in a pillAs global oncology races toward next-generation therapies, Avammune Therapeutics is betting on affordable, orally administered immunotherap...
- Volatility as opportunity, depends on framework of mind: 5 mid-caps from different sectors with upside potential of up to 31%The Indian stock market is no longer correcting only because of sentiment. It is now adjusting to the possibility of weaker numbers in the ...
- No easy contrarian sectoral bets left? SBI MF’s Dinesh Balachandran explains what investors should do nowDinesh Balachandran, Head–Investments, SBI Funds Management, runs some of SBI Mutual Fund’s (MF) largest schemes, including SBI Contra Fund...
- Wockhardt secures US FDA approval for antibiotic ZaynichWockhardt's novel antibiotic, Zaynich (cefepime and zidebactam), has received US FDA approval for complicated urinary tract infections. Thi...
- What to know about the Bundibugyo virus, a species of Ebola causing an outbreak in CongoA rare Bundibugyo virus outbreak in Congo, with over 200 deaths, lacks specific treatments or vaccines, complicating response efforts. Whil...
- Cipla is aiming for 40-50 global product filings in three years, says MD Achin GuptaCipla is charting its next growth phase with a strong focus on innovation, complex generics, and biosimilars. The company plans significant...
- Innovation, biosimilars, complex generics to drive Cipla's growth: Achin Gupta, MD & Group CEOAs Cipla approaches its centenary, the company is redefining its strategy by prioritizing innovation to amplify revenues. With ambitions to...
- She fainted in school from period pain for years; now the 27-year-old fights stage 4 cancer alone after losing her father, with no siblings by her sideRadhika Sapra endured years of dismissed menstrual pain, only to be diagnosed with stage 4 ovarian cancer at 22. Now 27, she battles the di...
- Covid is now hitting young Indians in a shocking new way, doctors say people in their 30s are suddenly needing hip replacementsHip replacement surgeries among Indians in their 30s and 40s have reportedly risen by nearly 40 per cent in the post-Covid period. Doctors ...
Load More
